30.44MMarket Cap-1370P/E (TTM)
5.7000High5.1011Low3.74KVolume5.5750Open5.6128Pre Close20.00KTurnover0.13%Turnover RatioLossP/E (Static)5.39MShares8.480052wk High-85.58P/B16.83MFloat Cap3.448852wk Low--Dividend TTM2.98MShs Float38400.0000Historical High--Div YieldTTM10.67%Amplitude3.4488Historical Low5.3510Avg Price1Lot Size
Pluri Inc Stock Forum
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division.
PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment.
This collaboration leverages Pluri's 47,000 square foot GMP cell production facility a...
Benzinga· just
The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
Pluri Collaborated With Wilk Technologies To Develop Human Breast Milk-derived Food Production On A Commercial Scale
NEWS
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 ...
Benzinga· 1 min ago
Leading biotechnology company, Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells using proprietary technology and announced it was granted a new U.S. patent titled, "System and Methods for Immune Cells Ex...
No comment yet